Pivotal study results regarding finerenone in patients with Type 1 Diabetes and Chronic Kidney Disease were published on 2026-01-01 in the New England Journal of Medicine. This publication details findings from the FINE-ONE study, which investigated the efficacy and safety of the treatment in this patient population.
Background
Finerenone is a medication under investigation for its potential role in managing chronic kidney disease, particularly in patients with diabetes. The coexistence of Type 1 Diabetes and Chronic Kidney Disease presents significant challenges due to the progressive nature of both conditions and their impact on patient health outcomes. The publication of these results marks a significant step in understanding finerenone's profile in this specific and complex patient population, where treatment options are often limited.
Trial design
The study, known as FINE-ONE, was designed to evaluate how well the study treatment finerenone works and its safety profile. It focused on individuals with Chronic Kidney Disease in conjunction with Type 1 Diabetes.
What this means
The publication of the FINE-ONE study results provides clinicians and researchers with detailed information regarding finerenone's performance in patients with Type 1 Diabetes and Chronic Kidney Disease. These findings are now available for thorough review, allowing the medical community to assess the potential implications for patient care, treatment strategies, and future research directions in this complex patient population, which often faces a high burden of disease progression.
Source
The information regarding this pivotal publication was obtained from PubMed. The article, titled "Finerenone in Type 1 Diabetes and Chronic Kidney Disease," was published on 2026-01-01, and is accessible via pubmed.ncbi.nlm.nih.gov.